Genscript Biotech (HKG:1548) expects an increase in net profit in 2024, compared with the corresponding period of the previous year, according to a Sunday filing with the Hong Kong Bourse.
The company attributed the increased net profit to a one-time, tax-free unrealized gain of $3.2 billion from Legend Biotech's deconsolidation and future revenue from Probio's sublicensing, despite a $124 million fair value loss.
The life science research business plans to publish its annual results by the end of March.
The company's shares were down over 2% in the recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。